Once daily dosing will in part level the playing field for patient groups who do not use ribavirin.
It depends on the labeling of the (likely) approval of the Merck program, it could be important depending on how that gets labeled.
That program will be once per day, but there may be some riba use for some groups, or extended treatment times beyond 12 weeks
It is not uncommon that ribavirin dosing can be reduced due to AE's. Mine was cut in half, from 1200mg to 600mg (6 pills to 3 pills) due to anemia (in a GILD trial -Sov/Ledi/riba).
In a dose reduction scenario, one could actually just do it once per day. I really had to take my riba in the morning, since taking them at night produced the same result as taking Ritalin before bedtime. : )
===============
Having the drugs all co-formulated/once in the morning makes more certain that all of the DAA drugs are taken; reduces the chance of missing a dose in the evening (in this case ABT-333).
Anything that helps maintain Abbvie's position could help the 2nd gen program launch to some degree.
I agree; it's not huge, but I think it's a definite benefit, for roughly a year before the 2nd gen program is expected to be approved. It could mitigate Merck erosion of market share to some degree.
===========
Also Is this a non issue for G-4 or G-1 in japan? (no ABT-333 in Japan program?)
Or could the once daily of this program be a benefit? (higher SVR rates?)
Market Data 
Markets 
AI
